Etoposide

Catalog No.S1225 Synonyms: VP-16, VP-16213

Etoposide Chemical Structure

Molecular Weight(MW): 588.56

Etoposide is a semisynthetic derivative of podophyllotoxin, which inhibits DNA synthesis via topoisomerase II inhibition activity.

Size Price Stock Quantity  
In DMSO USD 91 In stock
USD 70 In stock
USD 280 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 58 Publications

Purity & Quality Control

Choose Selective Topoisomerase Inhibitors

Biological Activity

Description Etoposide is a semisynthetic derivative of podophyllotoxin, which inhibits DNA synthesis via topoisomerase II inhibition activity.
Targets
Topo II [2]
(Cell-free assay)
In vitro

Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA, which induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle. [1] Etoposide inhibits the growth of murine angiosarcoma cell line (ISOS-1) in a 5 days-period with IC50 of 0.25 μg/mL. Cell growth of normal murine microvascular endothelial cells (mECs) is less sensitive to Etoposide with IC50 of 10 μg/mL). [2] Etoposide treated for 6 hr inhibits colonies of tetraploid variant of the human leukemic lymphoblast line CCRF-CEM with IC50 of 0.6 μM. [3] Etoposide treated for 2 hr inhibits growth of human pancreatic cancer cell line Y1, Y3, Y5, Y19, YM. YS, and YT with IC50s of 300 μg/mL, 300 μg/mL, 300 μg/mL, 91 μg/mL, 0.68 μg/mL, 300 μg/mL, 300 μg/mL, and 260 μg/mL, respectively. [4] Etoposide exposed for 1 hr inhibits growth of human glioma cell lines CL5, G142, G152, G111, and G5 with IC50 of 8, 9, 9.8, 10, and 15.8 μg/mL respectively for 12 days. Under same condition, the IC90 value is attained in cell lines CL5, G152, G142, and G111 at 26, 27, 32, and 33 μg/mL. Etoposide inhibition of topoisomerase II is homogeneous for each cell. The average inhibition rates are 15%, 21.8%, 31.8%, 41.5%, and 49.5% for 1, 2, 4, 8, and 16 μg Etoposide, respectively. [5]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Kelly MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXS1SnJxUUN3ME2wMlEz6oDLwsJihKkxNjBzIN88US=> NEPlR20zPTl4MEK4Ni=>
KellyCis83 M{jNfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEntTndKSzVyPUCuNVbjiIoEsfMAjVAvODJizszN MknSNlU6PjB{OEK=
SK-N-AS NWmxdIV2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYHJR|UxRTBwMkVihKnDueLCiUCuNFMh|ryP NWrL[INmOjV7NkCyPFI>
SK-N-ASCis24 NXq3S5dmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFLYVnFKSzVyPUCuOVfjiIoEsfMAjVAvOTFizszN Ml\UNlU6PjB{OEK=
U87 M1ThVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF[0SXQxNTVyIN88US=> MYW0PEBp MVPk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHlid3jpZ4gh[2GwIHLlJIVvcGGwY3XkJIJ6KHOrbHnibY5qdg>? MnmwNlU4PTB{N{O=
HCT116 MnTYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVzQSY43OC53LUKuOUDPxE1? M17oS|Q5yqCqwrC= MnyyTWM2OD1zLkezxsDDucLiMD6yNeKh|ryP NX;pVVhQOjV5NE[3OlM>
HT-29 MnvyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NELDWGUxNjVvMj61JO69VQ>? M164c|Q5yqCqwrC= M3HaOWlEPTB;Nz6yxsDDucLiMT6wOOKh|ryP NUL3S2Q5OjV5NE[3OlM>
Caco2 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M33zelAvPS1{LkWg{txO M{K5dFQ5yqCqwrC= NUHDSphMUUN3ME23MlI3yqEEsdMgNU43QMLizszN MXmyOVc1Pjd4Mx?=
COLO 205 NV7ONFIzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{LDfVAvPS1{LkWg{txO NYX4ZXU3PDkEoHlCpC=> Mk\YTWM2OD1zLk[xxsDDucLiMD6wNuKh|ryP M2LOeVI2PzR4N{[z
SW480 NFS4e4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV2wMlUuOi53IN88US=> NUWyNoNKPDkEoHlCpC=> M1j6cGlEPTB;ND65NuKhyrIEoECuN|PDqM7:TR?= MWCyOVc1Pjd4Mx?=
HEK293T M4XIZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NELLcGEyNTVizszN NYK4eXF2PDkEoHlCpC=> NUPmXFdkUUN3ME2yMlQzyqEEsdMgNE4xPcLizszN M4G5WVI2PzR4N{[z
Hep3B  MkSwSpVv[3Srb36gRZN{[Xl? Ml;ENVAh|ryP Ml32OFjDqGkEoB?= MmfidoVlfWOnczD0bIUh\W6qYX7jbY5oKGWoZnXjeEBw\iCETWCtOi=> M2TUOVI2PjN|NU[0
Hep3B  M1LGTGZ2dmO2aX;uJGF{e2G7 NYrkRpR6OC5zLUGwJO69VQ>? MXmyOEBp M3vrVJN2eHC{ZYPz[ZMhfGinIHX4dJJme3Orb36gc4YhcGWyY3nkbY4hdVKQQR?= MnXJNlU3OzN3NkS=
HEK293 Ml7rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MU\JR|UxRTdwMUVCpOKyyqByLkO2xsDPxE1? NIizbIkzPTZyM{GyNi=>
DU145 M3;EXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkDGTWM2OD1{LkK4xsDDucLiMD6wOOKh|ryP MUWyOVYxOzF{Mh?=
HCT15 MknmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mmm4TWM2OD1yLkixxsDDucLiMD6wNeKh|ryP NUXmcZV4OjV4MEOxNlI>
T47D Mk\wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M13UTmlEPTB;Mz6xPOKhyrIEoECuNVHDqM7:TR?= Ml3lNlU3ODNzMkK=
SMMC-7721 NHu1R2lHfW6ldHnvckBCe3OjeR?= MX20NEDPxE1? NVXiU25TPDhiaB?= NGfwOmZFVVOR MkjPbY5lfWOnczFOt2gzSVhiZn;jbUBnd3KvYYTpc44> NXu3fY9SOjV3NESzOlE>
MDA-MB-231 NGPUSnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVS3NuKhcA>? NWDxe5E{UUN3ME2yNU4zyqEEsdMgOE4zyqEQvF2= MnXTNlU1QDZ{MUm=
MCF-7 NUPBPYFlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4\2OVczyqCq M2TNR2lEPTB;MUCuPeKhyrIEoEKuNeKh|ryP NXK0UIozOjV2OE[yNVk>
Jurkat NG\FOJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWm3NuKhcA>? NF7QPIVKSzVyPUGuNuKhyrIEoEGuOeKh|ryP MVmyOVQ5PjJzOR?=
HeLa MnLXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEi1fZQ4OsLiaB?= NVrRWYZ6UUN3ME2zMlnDqMLzwrCyMlPDqM7:TR?= MlTpNlU1QDZ{MUm=
MCF7  MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3Ls[VUuOTByIN88US=> NFW0ZWs4KGR? NXTDTFhbcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NY\vUVJuOjV2N{K2NVk>
K562 NYjQVmdlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXm3NuKhcA>? M1frbGlEPTB;MD6yPeKh|ryP NWjhXlV1OjV{OEK2OVM>
K/VP.5 NI\OUmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV[3NuKhcA>? MkHYTWM2OD12LkpCpO69VQ>? M3TNTlI2Ojh{NkWz
SH-EP  NXe5R3FoTnWwY4Tpc44hSXO|YYm= NELJ[WIzOMLizsznM41t NHvCRnkzPMLiaB?= NUDQZ|FDcW6lcnXhd4V{KHSqZTDlfJBz\XO|aX;uJI9nKGWwZH;n[Y5wfXNiRFXQVC=> MX2yOVI3OTl6MR?=
SCC25 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3PuTVI1yqCq Ml;CTWM2OD12Mz6zxsDDucLiMT6xNuKh|ryP NGDzdYIzPTJ{MEeyPS=>
CAL27 M2\kUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYSyOOKhcA>? MWfJR|UxRTV{LkJCpOKyyqBzLkC5xsDPxE1? MYOyOVIzODd{OR?=
FaDu Mlf6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3fYWFI1yqCq MUTJR|UxRTJ3Lki5xsDDucLiMT6xN:Kh|ryP NV3yb5lJOjV{MkC3Nlk>
SCC25 MoXES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml;0OFjDqGh? M{PXdWlEPTB;MkCuPFbDqMLzwrCxMlA4yqEQvF2= MU[yOVIzODd{OR?=
CAL27 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIDxZWE1QMLiaB?= MVPJR|UxRTF6LkK0xsDDucLiMT6xOeKh|ryP Mkm0NlUzOjB5Mkm=
FaDu MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlHDOFjDqGh? MnTCTWM2OD14LkSzxsDDucLiMT6xN:Kh|ryP M2HsTVI2OjJyN{K5
SCC25 NF21[49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnniO|LDqGh? NEnadJpKSzVyPUiuOFHDqMLzwrCxMlEyyqEQvF2= Mn;uNlUzOjB5Mkm=
CAL27 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVjFbo5yPzMEoHi= NX\LR3NFUUN3ME20MlI4yqEEsdMgNU4yPMLizszN MX2yOVIzODd{OR?=
FaDu NETuOIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NELyepk4OsLiaB?= NYr4UlhEUUN3ME21MlAzyqEEsdMgNU4yPcLizszN MYeyOVIzODd{OR?=
MCF-7 NG\x[ndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkH4OFjDqGkEoB?= MoDWSG1UVw>? MWDJR|UxRTdwMtMgxtHDqDBwONMg{txO M4qzNFI2OjF4M{e4
T-47D MlPDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3LiZ|Q5yqCqwrC= NHXobXFFVVOR NIP5S2lKSzVyPUeuO:KhyrIEoECuO:Kh|ryP MVSyOVIyPjN5OB?=
MDA-MB-231 MnniS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH:5O5U1QMLiaNMg M2SxbWROW09? NEW3WoFKSzVyPUGyMljDqMLzwrCxMlDDqM7:TR?= MlfVNlUzOTZ|N{i=
DU145 NVqzVYtGSXCxcITvd4l{KEG|c3H5 NInDdmEyOC1zMECg{txO NH65N4w5KGh? NVTSSnJ3TE2VTx?= NFOwenhqdmS3Y3XzJINmdGxiZHXheIghe2mpbnnmbYNidnSueTDpckBiKH[ncomgcI94KGOxbnPlcpRz[XSrb36= NX7kbIl3OjVzNEm2PFE>
DU145 stem-like M2rNW2Fxd3C2b4Ppd{BCe3OjeR?= MoHINVAuOTByIN88US=> NEDhPY05KGh? M165VmROW09? MUHpcoR2[2W|IHPlcIwh\GWjdHigbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= MYqyOVE1QTZ6MR?=
DU145 NIi2fmJHfW6ldHnvckBCe3OjeR?= MU[xNE0yODBizszN M4PqVlIhcA>? NUWxOnlQTE2VTx?= MWHpcoNz\WG|ZYOgeIhmKHCFSFuxJIV5eHKnc4Ppc44h[W6mIHTlZ5Jm[XOnczD0bIUheEOKS{Gg[ZhxemW|c3nvckBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NULRNYVGOjVzNEm2PFE>
DU145 stem-like MmnySpVv[3Srb36gRZN{[Xl? NEXsRW0yOC1zMECg{txO MV6yJIg> MlzoSG1UVw>? MXvpcoNz\WG|ZYOgeIhmKHCFSFuxJIV5eHKnc4Ppc44h[W6mIHTlZ5Jm[XOnczD0bIUheEOKS{Gg[ZhxemW|c3nvckBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NWjoTmN{OjVzNEm2PFE>
UW228-3 M4XrfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVjKclBDOC5yMT2zNFAh|ryP MWC0PEBp MXvEUXNQ MVvJR|UxRTBwOUpCpO69VQ>? M{\uXFI2OTF7MUi1
NSCs MorFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1n6dVAvODFvM{CwJO69VQ>? NXHTOodXPDhiaB?= NGLqWFFFVVOR NWG3VlJtUUN3ME2wMlMuO8LizszN NV7kOpUyOjVzMUmxPFU>
MKL-1  NEfxbHBHfW6ldHnvckBCe3OjeR?= MmnmNVAuOTByMDDuUS=> NIP2eXU1KGR? NYO3TXhLcW6mdXPld{B1cGViaX7keYN1cW:wIH;mJG1JSy2LIHX4dJJme3Orb36= MW[yOVEyPjd3NB?=
MCF7 EV NHPSWHdHfW6ldHnvckBCe3OjeR?= M1jGcVExNTFyMDFOwG0> M3PuZ|LjiImq M3LpUYlv\HWlZYOgdJJw\HWldHnvckBw\sLizsPINmFZ NIHJUYYzPTB6OEKwNy=>
MCF 7BMI1 NUjYVZZzTnWwY4Tpc44hSXO|YYm= NF\WXVYyOC1zMECg{txO NHfBNo8z6oDLaB?= NVzEdFVOcW6mdXPld{Bxem:mdXP0bY9vKG:owrFOt2gzSVh? M{fkO|I2ODh6MkCz
MCF7 EV NInF[nZHfW6ldHnvckBCe3OjeR?= M3;EZ|ExNTFyMDFOwG0> MojYNwKBkWh? NIrHfJpGXE:SIHnu[JVk\XNiQWTNJIFkfGm4YYTpc44> NEXvfVEzPTB6OEKwNy=>
MCF7 BMI1 MmPPSpVv[3Srb36gRZN{[Xl? Ml7PNVAuOTByIN88US=> MorxNwKBkWh? MV7FWG9RKGmwZIXj[ZMhSVSPIHHjeIl3[XSrb36= MUWyOVA5QDJyMx?=
HepG2 MmDJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1i5bWROW00EoB?= MleyTWM2OD1|MD6xOuKhyrIEoECuOVDDqM7:TR?= NGrTcGgzPTB5OEOxNS=>
MOLT-3 NWD0T2hyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlXMSG1UV8Li MmX2TWM2OD1yLkC1NeKhyrIEoECuNFAzyqEQvF2= NXTQZ|dHOjVyN{izNVE>
HT1080 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUSxMVExOCEQvF2= NYLBNZh5PC9{ND:0PEBp Ml3VSG1UV8Li MX\pcoR2[2W|IHPlcIwh\GWjdHigd4lodmmoaXPhcpRtgSCrbjDhJJZmenlibH;3JINwdmOnboTyZZRqd25? M3[1R|I2ODd6ME[0
HT1080 MWLGeY5kfGmxbjDBd5NigQ>? M3vGXVAvODByMT2xNFAh|ryP NXi2[ZRJOS1{NDDo NFjt[4FFVVORwrC= NIr4XYVqdmS3Y3XzJJAueDV|KIPldlE2MSCrbjDic5RpKHSrbXWtJIFv\CClb37j[Y51emG2aX;uMYRmeGWwZHXueEBu[W6wZYK= MU[yOVA4QDB4NB?=
HT1080 NYTNSJJIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF;zWlYxNjByMEGtNVAxKM7:TR?= MkL1NlQhcA>? NUXISlI5TE2VT9Mg NHO5PFhk[XW|ZYOgZY4hcW6lcnXhd4UhcW5idHjlJI52dWKncjDv[kBk\WyuczDpckBIOi:PLDD3bIlt\SCmZXPy[YF{cW6pIGOgZY5lKEdzIIDoZZNmKGOnbHzz M2TUTFI2ODd6ME[0
HD-MY-Z M2KxXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1y5blI1NzR6L{eyJIg> M362UWlEPTExvK6xNFAh|ryP NF3CToYzPTB2OEKzOi=>
DOHH-2 NEPDV49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYWyOEBp MY\JR|Ux97zgMUCwJO69VQ>? NYLje4ZwOjVyNEiyN|Y>
DOHH-2 MnjJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVS0PEBp M{\M[WlEPTB;MUmuPeKh|ryP NH3kR|YzPTB2OEKzOi=>
DOHH-2 M2PzcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEC1TVY4OiCq NGXMS2hKSzVyPUZCpO69VQ>? NXLZSokzOjVyNEiyN|Y>
REH NYT3[JluT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV:yOEBp NITvcI9KSzVyPUCuNFI4yqEQvF2= MWmyOVA1QDJ|Nh?=
REH M3LvNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXK0PEBp NYTUWVNGUUN3ME2wMlAyPMLizszN NUfMS3o2OjVyNEiyN|Y>
REH MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUfPSoJ[PzJiaB?= MYfJR|UxRTBwMEG1xsDPxE1? NX;WRZp4OjVyNEiyN|Y>
HH M3rRNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXTYZ3U3OjRiaB?= NFzv[XlKSzVyPUGwOE44yqEQvF2= MVGyOVA1QDJ|Nh?=
HH M3PFV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH74V|Y1QCCq MXfJR|UxRTR6LkdCpO69VQ>? NV3VRXdGOjVyNEiyN|Y>
HH MonES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEPXN|Q4OiCq M{WwSGlEPTB;MUSuO:Kh|ryP NFHaPXQzPTB2OEKzOi=>
HuT-78 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIfU[5QzPCCq NILLR3VKSzVyPUmuN:Kh|ryP NH;4VmczPTB2OEKzOi=>
HuT-78 MlfjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYW2TohbPDhiaB?= MkLvTWM2OD12LkRCpO69VQ>? NWfLVZBKOjVyNEiyN|Y>
HuT-78 M2jBfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M37ZeVczKGh? M1XnW2lEPTB;ND6yxsDPxE1? MljMNlUxPDh{M{[=
OPM-2 M3;0R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1S2TlI1KGh? NEHPdWFKSzVyPUK0MlHDqM7:TR?= MYeyOVA1QDJ|Nh?=
OPM-2 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEPxPG41QCCq MWXJR|UxRTUEoN88US=> MWSyOVA1QDJ|Nh?=
OPM-2 M{Wz[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mlr3O|IhcA>? MWfJR|UxRTFwM9Mg{txO MorpNlUxPDh{M{[=
RPMI-8226 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1fmbVI1KGh? NHnnbGRKSzVyPUGwOk43yqEQvF2= M4DiOFI2ODR6MkO2
RPMI-8226 MnK4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn3qOFghcA>? MkTJTWM2OD17MT6xxsDPxE1? MVKyOVA1QDJ|Nh?=
RPMI-8226 NVPjO4ZxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkPNO|IhcA>? MnnkTWM2OD1zND65xsDPxE1? Ml;INlUxPDh{M{[=
U-266 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk\LNlQhcA>? Mlf1TWM2OD16Nj6yxsDPxE1? Mn3ZNlUxPDh{M{[=
U-266 NEGyeoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2TZVFQ5KGh? NEnBOmJKSzVyPU[4MlTDqM7:TR?= MUCyOVA1QDJ|Nh?=
U-266 NI\EXIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYDnSHR[PzJiaB?= MlLDTWM2OD1{Nz60xsDPxE1? NF:2[JkzPTB2OEKzOi=>
Kelly NXXoPGptT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX;DfnVIOC1zMDFOwG0> MYi3NuKhcA>? MV7JR|UxRTFwNUG4xsDPxE1? MUGyOVAxQDlyMB?=
SH-SY5Y  MojGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4TIbVAuOTBizszN NXfmRpJLPzMEoHi= M3PHdGlEPTB;MD63OVTDqM7:TdMg M170OFI2ODB6OUCw
SK-N-AS M{\vW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MljrNE0yOCEQvF2= NYHZUnpRPzMEoHi= NVLPfnhOUUN3ME2xMlcyOsLizszNxsA> MoXLNlUxODh7MEC=
SK-N-DZ NEP1fHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGLHeXMxNTFyIN88US=> NYThZ|NIPzMEoHi= MojnTWM2OD13LkS4OeKh|ryP Mn\2NlUxODh7MEC=
HepG2 NF3MeJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYO0POKhcA>? MVXEUXNQyqB? MorYTWM2OD1zMz62OeKhyrIEoECuPVLDqM7:TR?= MXWyOFk6PjF|Nh?=
A549 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlzROFjDqGh? MVvEUXNQyqB? Mm\TTWM2OD1{NEGuPeKhyrIEoEOxMlI{yqEQvF2= MUiyOFk6PjF|Nh?=
MCF7 M3fF[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmfIOFjDqGh? NEHqfJFFVVORwrC= M4TjVmlEPTB;OEGuNFnDqMLzwrCxOE4zOcLizszN NF3zO5MzPDl7NkGzOi=>
HL-60  MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NETzelY4OsLiaB?= M4S2VWlEPTB;MD6xNwKBjc7:TR?= NFm1U48zPDl7M{CxOC=>
HL-60[R] Ml\sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW\meG1YPzMEoHi= M3\qfGlEPTB;Mz6xNwKBjc7:TR?= MUKyOFk6OzBzNB?=
MIAPACA MlOwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH;DRmtIUTVyPUGuN{DDuSByLkCzJO69VQ>? MlXpNlQ6PTN6MkG=
MCF-7 M1HwUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHWydWxIUTVyPUCuNlUhyrFiMD6xJO69VQ>? M1T6VVI1QTV|OEKx
HeLa NHXXU4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{\XfGdKPTB;MD62OEDDuSByLkSg{txO MXqyOFk2Ozh{MR?=
MO59K  M37xZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXO3JIQ> M4TRS2lEPTB;MD6xO-KBjc7:TR?= Mn;RNlQ6PTN3NkG=
MO59J Mn63S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXjVU2tVPyCm NFjxR21KSzVyPUCuNgKBjc7:TR?= NYfBOoNuOjR7NUO1OlE>
ME 180 NVjTe21vT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIPPbWc1QMLiaNMg MW\JR|UxRThwOdMgxtHDqDBwM,MAie69VQ>? MUCyOFk2OzB{Nx?=
MCF-7 NVrMXI9KT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{PMV|Q5yqCqwrC= M1rUUmlEPTB;MkOuPUDDuSByLkRihKXPxE1? MVyyOFk2OzB{Nx?=
HeLa NVLUcI1XT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVrmcVNbPDkEoHlCpC=> NVHMcIJiUUN3ME20MlcyKMLzIEGuOQKBjc7:TR?= M2[zZVI1QTV|MEK3
MDA-MB-453 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX[1[o5pPDkEoHlCpC=> MXfJR|UxRTF{LkWgxtEhOC56NfMAie69VQ>? NGXnV2kzPDl3M{CyOy=>
MDA-MB-231 NEftOHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYf5SocxPDkEoHlCpC=> Ml;KTWM2OD1{ND6yNkDDuSB{Lkm05qCG|ryP MmTFNlQ6PTNyMke=
PC-3 NGjK[WVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGSy[XI1QMLiaNMg MUfJR|UxRTF2LkSgxtEhOy5{M,MAie69VQ>? M2TTeFI1QTV|MEK3
HT-29 NGnGe|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnH1OFjDqGkEoB?= NIHnRlBKSzVyPUKxMlQ2KMLzIEOuPFfjiIYQvF2= MlnpNlQ6PTNyMke=
BGC-823 MnHUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1vOUVQ5yqCqwrC= M3GzNWlEPTB;NEOuO|QhyrFiNT6xN-KBjc7:TR?= M1X1XFI1Pzl|OEe3
HeLa M4riNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXLpWI5JPDkEoHlCpC=> NXv4WWJ4UUN3ME2yNFkvQTBiwsGgNVMvPDJi4pEF{txO M1\WZlI1Pzl|OEe3
A549 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2nxeVQ5yqCqwrC= NWrJS415UUN3ME2xN|kvPTRiwsGgO{4xPeLChd88US=> NIT3R|gzPDd7M{i3Oy=>
HK-2 NHXNXoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUK0POKhcMLi M3r0XmlEPTB;OT6xO{DDuSBzLkW45qCG|ryP MoXONlQ4QTN6N{e=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p53 / p-p53 / Acetyl-p53 / TF-IIB; 

PubMed: 23800173     


Western blotting analysis of p53 levels and the indicated p53 post-translational modifications in the nucleus and cytoplasm of U-2 OS cells treated with no drug, 1 μmol/l etoposide (treated for 24 hours) and 100 μmol/l etoposide (treated for 12 hours), re䲧疝Ỵ疞㧀疜膉痘 瘿삨ՂᾰƌՂĀ 㺣痖帉痖Ѐ瑖堘𢡄빢᎒ՂĀ鑸᎒彿堙奋堙巫堙᎒ﻺ᎒彿堙ﻮ᎒塚堙ﻺ᎒ꍈ堞빢᎒學堙漸堞圔堙빢᎒圞堙圭堙𢡄玚Wᾰƌ ᾰƌ戤瘯Ɖ뙠ෆ䐺痖暼瘿뙠ෆᾰƌ 뙠ෆÐ㺣

p53 / p21 / c-Myc / PARP ; 

PubMed: 20212154     


Myc is repressed at the posttranscriptional level following etoposide treatment. HEK293 cells were treated with etoposide at the indicated concentrations for 24 h. Parallel samples were taken for western and northern analysis as indicated. 

23800173 20212154
Immunofluorescence
COX IV; 

PubMed: 29221178     


Panel 1 (untreated) depicts the mitochondrial distribution by visualizing the expression of Cox IV in U87(WT) cells. Panel 2 (etoposide treated) represents the distribution of mitochondria in U87(RETO) cells after 10 days of drug exposure as visualized by䲧疝Ỵ疞㧀疜膉痘 瘿삨ՂᾰƌՂĀ 㺣痖帉痖Ѐ瑖堘𢡄빢᎒ՂĀ鑸᎒彿堙奋堙巫堙᎒ﻺ᎒彿堙ﻮ᎒塚堙ﻺ᎒ꍈ堞빢᎒學堙漸堞圔堙빢᎒圞堙圭堙𢡄玚Wᾰƌ ᾰƌ戤瘯Ɖ

γH2AX / pATM ; 

PubMed: 19858003     


HeLa cells were treated with vehicle (Ctl), 6 Gy IR (IR) or 25 μM etoposide (ETO). Co-localization (yellow signal in the overlay (OL)) of gH2AX (red) and pATM (green). Scale bar = 20 μm.

MDC1; 

PubMed: 19858003     


HeLa cells were treated with vehicle (Ctl), 6 Gy IR (IR) or 25 μM etoposide (ETO). Co-localization of gH2AX with MDC1.

pDNA-PKcs; 

PubMed: 19858003     


HeLa cells were treated with vehicle (Ctl), 6 Gy IR (IR) or 25 μM etoposide (ETO). Co-localization of gH2AX with pDNA-PK.

p53; 

PubMed: 27515249     


p53 localization in untreated and 12-h etoposide treated CD41+ MK cells. Cells were stained with anti-p53 antibody. TOTO-3 was used to stain the nucleus. Scale bar=20 μm.

YAP; 

PubMed: 27515249     


(D) YAP localization in untreated CD41+MK cells and CD41+ MK cells treated by 10 μM etoposide for five hours on day 10 of culture. Cells were stained with anti-YAP antibody. DAPI was used to stain the nucleus. Cells (150) were counted and categorized acco䲧疝Ỵ疞㧀疜膉痘 瘿�෋ᾰƌ෋à 㺣痖帉痖Ѐ瑖堘𢡄빢᎒෋à鑸᎒彿堙奋堙巫堙᎒ﻺ᎒彿堙ﻮ᎒塚堙ﻺ᎒ꍈ堞빢᎒學堙漸堞圔堙빢᎒圞堙圭堙𢡄玚Wᾰƌ ᾰƌ戤瘯Ɖ삨Ղ䐺痖暼瘿삨Ղᾰƌ 삨ՂÐ㺣痖삨Ղ€𢡄사Ղ€䀷痗사Ղ౴사Ղ㵶痗사Ղ뺖᎒泌Itemセ᎒Count﫨呂샜Ղ

29221178 19858003 27515249
Growth inhibition assay
Cell viability ; 

PubMed: 22615609     


Effect of etoposide on HEK293 cell viability. Cells were seeded at 104 in 96-well plates and treated with etoposide (50,100,150 and 200µM) for 24 hrs and compared to nontreated cells (control). At the end of treatment period, cell viability was measured u䲧疝Ỵ疞㧀疜膉痘 瘿삨ՂᾰƌՂĀ 㺣痖帉痖Ѐ瑖堘𢡄빢᎒

22615609
In vivo Etoposide administrated as a single agent is found to been ineffective in many xenografts growth, such as Heterotransplanted Hepatoblastoma NMHB1, and NMHB 2, [6] human neuroblastoma xenograft, [7] and human gastrointestinal cancer xenograft, [8] while the dose of 10 mg/kg i.p. Etoposide inhibits murine angiosarcoma cell ISOS-1 tumors in 36% of controls. [2] Etoposide induces tumor immunity in Lewis lung cancer. A single administration of 50 mg/kg Etoposide i.p., induces a 60% survival of C57B1/6 mice injected with Lewis lung cancer cell (3LL) over 60 days. About 40% of these surviving mice reject a subsequent challenge with 3LL, while none of control mice survive beyond 30 days. 3LL cells which have survived an 90% lethal concentration of Etoposide in vitro kill 75% of recipient mice, but 60% surviving mice reject challenge with 3LL. Splenocytes harvested from tumor rejecting mice protect naive mice injected with 3LL. [9]

Protocol

Kinase Assay:[5]
- Collapse

Topoisomerase II activity assay:

Nuclear extracts are prepared, and nuclei are isolated. The activity of topoisomerase II is calculated from the percentage of decatenation obtained. Tritiated kinoplast DNA (KDNA 0.22 μg) is used as a substrate. Etoposide and topoisomerase II are incubated for 30 min at 37 ℃ and are stopped with 1% sodium dodecyl sulfate (SDS) and proteinase K (100 μg/mL). The percentages of decatenation and inhibition of topoisomerase II by Etoposide are obtained.
Cell Research:[5]
- Collapse
  • Cell lines: Human glioma cell lines CL5
  • Concentrations: 80 μg/mL
  • Incubation Time: 1 hour
  • Method: After the Etoposide treatment, cells are removed from the dish with phosphate-buffered saline (PBS) containing 0.03% trypsin and 0.27 mM ethylenediaminetetraacetic acid (EDTA) and are diluted into culture dishes in appropriate numbers to yield between 20 and 200 colonies. After 12 days, cultures are fixed with methanol-acetic acid, stained with crystal violet, and scored for colonies containing more than 50 cells. The standard errors are typically less than 15% of the mean value unless otherwise stated.
    (Only for Reference)
Animal Research:[2]
- Collapse
  • Animal Models: Murine angiosarcoma xenografts ISOS-1
  • Formulation: Saline
  • Dosages: 10 mg/kg
  • Administration: i.p. every day for 5 days from day 7
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (169.9 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+40% PEG 300+5% Tween 80+ddH2O
For best results, use promptly after mixing.
15mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 588.56
Formula

C29H32O13

CAS No. 33419-42-0
Storage powder
in solvent
Synonyms VP-16, VP-16213

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT03264131 Recruiting Drug: Brentuximab Vedotin|Drug: CHEP Lymphoma|Adult T-Cell Leukemia/Lymphoma|Lymphatic Diseases UNC Lineberger Comprehensive Cancer Center|Seattle Genetics Inc. October 15 2018 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Regarding the Etoposide S1225, do you have any data of the inhibition sepcificity of this product? It will inhibit other enzymes other than TOP2A?

  • Answer:

    According to the available published data, the inhibition of Etoposide is specific to TOP2A. But there're also two papers showing that Etoposide could inhibit the p34cdc2 Kinase Activity: 1. http://cancerres.aacrjournals.org/content/52/7/1817.short ; 2. http://cancerres.aacrjournals.org/content/50/12/3761.short.

Topoisomerase Signaling Pathway Map

Related Topoisomerase Products

Tags: buy Etoposide | Etoposide supplier | purchase Etoposide | Etoposide cost | Etoposide manufacturer | order Etoposide | Etoposide distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID